Clinical Trials Logo

Clinical Trial Summary

This study is designed to randomly assign breast cancer patients requiring and agreeing to chemotherapy into two groups. One group will be receive an exercise prescription aimed at increasing physical activity by a minimum of 10 MET (metabolic equivalent task) hours per week. The other group will not receive a exercise prescription but their activity will be recorded. The hypothesis is that participants that are most active will exhibit improved chemotherapy completion rates, improved fitness, less fatigue and lower levels of markers for inflammation in their blood.


Clinical Trial Description

This is a prospective, randomized, single institution feasibility trial. The efficacy of an exercise intervention during chemotherapy for sedentary breast cancer patients will be tested. The investigators goal is to recruit 120 women and men. Assuming 20% attrition rate, 96 will be randomized to two arms, comparing patients assigned to a physical activity program plus general health education materials versus patients assigned to receive standard general health education materials only. Study measures will be obtained before intervention, at 24 weeks, and at the end of the intervention, approximately week 32. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02159157
Study type Interventional
Source Dartmouth-Hitchcock Medical Center
Contact
Status Completed
Phase N/A
Start date June 2014
Completion date December 31, 2018

See also
  Status Clinical Trial Phase
Completed NCT02816164 - A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia Phase 4
Completed NCT02816112 - Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia Phase 4
Completed NCT03946683 - Cyberknife for Early Stage Breast Cancer N/A
Recruiting NCT04458532 - Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer N/A
Completed NCT01162200 - Cyberknife® Partial Breast Irradiation (PBI) for Early Stage Breast Cancer Phase 1
Completed NCT01965522 - Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer Phase 2
Completed NCT00309569 - Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients Phase 3
Terminated NCT01545648 - Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer Phase 2
Completed NCT02428114 - A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study) N/A
Active, not recruiting NCT02685332 - Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA Phase 1
Completed NCT01871116 - POWER-remote Weight Loss Program in Early Stage Breast Cancer N/A
Terminated NCT01166581 - Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates N/A
Recruiting NCT06311357 - Percent Weight Change in the Medical Supplement Group of Early Breast Cancer N/A
Terminated NCT02364960 - Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT)
Active, not recruiting NCT03561454 - A Registry of Intra-Operative Radiation Therapy (IORT) Using the Xoft ® Axxent ® eBx ™ System Patients
Completed NCT02485678 - A Pragmatic Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer N/A
Active, not recruiting NCT02297672 - Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant N/A
Completed NCT02335671 - Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy N/A
Completed NCT03102307 - Registry Trial to Evaluate the Clinical Utilization of Targeted Axillary Dissection (TAD)
Recruiting NCT04607473 - ABUS for Early-stage Breast Cancer N/A